Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
-1.11 (-2.53%)
Jul 18, 2024, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Revenue

Ultragenyx Pharmaceutical had revenue of $442.59M in the twelve months ending March 31, 2024, with 15.29% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $108.83M with 8.30% year-over-year growth. In the year 2023, Ultragenyx Pharmaceutical had annual revenue of $434.25M with 19.52% growth.

Revenue (ttm)
Revenue Growth
P/S Ratio
Revenue / Employee
Market Cap
3.87B USD

Revenue Chart


Fiscal Year End Revenue Change Growth
Dec 31, 2023434.25M70.92M19.52%
Dec 31, 2022363.33M11.92M3.39%
Dec 31, 2021351.41M80.38M29.66%
Dec 31, 2020271.03M167.32M161.32%
Dec 31, 2019103.71M52.22M101.41%
Dec 31, 201851.50M48.88M1,871.48%
Dec 31, 20172.61M2.48M1,863.91%
Dec 31, 2016133.00K--
Dec 31, 20150--
Dec 31, 20140--
Dec 31, 20130--
Dec 31, 20120--
Dec 31, 20110--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Alkermes 1.73B
Integer Holdings 1.63B
Inspire Medical Systems 660.91M
Guardant Health 603.73M
Axsome Therapeutics 251.02M
Merus 38.34M
Avidity Biosciences 10.87M
Crinetics Pharmaceuticals 1.97M
Revenue Rankings